Award
NIH Reporter #1R44NS149824-01
Development of a Non-Addictive Intranasal Nerve Block to Provide Rapid Acute Treatment for Headache Disorders
Recipient
OLFAX, LLC
Award Amount
$1,446,740.00
Ceiling
$1,446,740.00
Awarded
September 03, 2026
Identifier
1R44NS149824-01
The award funds the development of Relaspen, a nasal drug-device for rapid migraine relief through SPG blocks, aiming to provide a non-addictive, at-home treatment option with reduced side effects and costs.
Description
This project aims to develop Relaspen, a nasally administered drug-device combination that enables patients to perform sphenopalatine ganglion (SPG) blocks at home, providing rapid relief without severe side effects. The project includes designing the device, conducting in vitro and bench testing, human factors studies, and a 6-month toxicity study in canines to support FDA approval.